.Focus on: Neglected Tropical Diseases

The NTD epidemic

Although most Neglected Tropical Diseases (NTDs) are preventable and treatable, they sadly continue to be a heavy burden on the most vulnerable, disadvantaged people in the world. One person in seven suffers from one or more NTDs, with the vast majority of cases in low-and middle-income countries (LMICs).

NTDs are caused by a vast range of different parasites, bacteria and viruses, which primarily thrive in subtropical climates. They can be painful, blinding and disfiguring; each year they lead to the poor-health, disability and death of hundreds of thousands of people.

As they are often chronic and disabling, NTDs have enormous educational and economic impacts, keeping children out of school and adults out of work. NTDs mire communities in a cycle of poverty, and hinder progress towards the sustainable development agenda. The increased commitments from national governments and their partners to achieve the targets of the WHO NTD Roadmap means significant improvements to the health, wealth and quality of life of over 1 billion people worldwide.

One person in seven suffers from one or more NTDs, with the vast majority of cases in low-and middle-income countries. One person in seven suffers from one or more NTDs, with the vast majority of cases in low-and middle-income countries. Copyright GlaxoSmithKline

Our contribution

NTDs require a multi-stakeholder approach to drive further research tailored to developing needs, improve health policies and access to treatments, and boost healthcare system capacity. That is why the R&D biopharmaceutical industry combats NTDs in an integrated manner.

2017 marks the 5th anniversary of the London Declaration, where IFPMA member companies pledged 14 billion donated treatments to control or eliminate the ten neglected tropical diseases (NTDs) responsible for more than 90% of the global NTD burden. In 2015 alone, biopharmaceutical companies donated an estimated 2.4 billion tablets, enough for 1.5 billion treatments to prevent and treat NTDs.

To ensure that new generations of improved treatments and interventions are discovered, despite low commercial incentives in the area of NTDs, the biopharmaceutical industry engages in a variety of multi-sectoral research models. IFPMA member companies are involved in over 100 active R&D projects for NTDs, and are partnering with over 50 organizations, including renowned universities, non-governmental organizations and public and private sector institutes. The latest G-FINDER finds that “Industry investment in neglected disease R&D in 2015 was the highest ever recorded in the G-FINDER survey”. The pharmaceutical industry contributed USD471m to global R&D efforts, and is the only sector (compared to public and philanthropic sectors) to have recorded year-on-year growth for the last four years.

Adding to their R&D efforts and donations, IFPMA member companies are also involved in over 40 partnerships to assist countries to bolster the capacity of their health workforce and medical infrastructures to meet the needs of people with NTDs.

Programs focus on building health services that are accessible and staffed with qualified healthcare workers to enable the delivery of medicines and vaccines down the last mile. They also provide people living in endemic areas information to help prevent the spread of infection, and infrastructure programs to address water, sanitation and hygiene.

You can learn more about these programs and many others by following the link “Neglected Tropical Diseases” under Partnership Information to the right.

Join us in conversations around Neglected Tropical Diseases using the hashtags #NTDs, #NomoreNTDs, #BeatNTDs  on social media.

More information can be found here:

IFPMA Neglected Tropical Diseases webpage

WHO Neglected Tropical Diseases Webpage

WHO Neglected Tropical Diseases Roadmap

London Declaration

G-Finder 2016

WHO Global Partners Meeting on NTDs (19 April 2017)

Partnership information

Company(ies) AbbVie , Astellas , AstraZeneca , Bayer , Bristol-Myers Squibb , Daiichi Sankyo , Eisai , Eli Lilly and Company , GlaxoSmithKline , Johnson & Johnson , Merck , MSD , Novartis , Otsuka , Pfizer , Roche , Sanofi , Shionogi , Takeda

Therapeutic Focus Neglected Tropical Diseases

Disease(s) Buruli Ulcer, Chagas Disease, Cysticercosis, Dengue, Dracunculiasis (Guinea Worm), Ebola, Echinococcosis, Endemic Treponematoses (Yaws), Fascioliasis, Foodborne Trematodiases, Human African Trypanosomiasis (Sleeping Sickness), Leishmaniasis, Leprosy, Lymphatic Filariasis, Onchocerciasis (River Blindness), Podoconiosis, Schistosomiasis, Soil-Transmitted Helminthiasis, Trachoma, Zika

Region(s) East Asia & Pacific, Latin America & Caribbean, Middle East & North Africa, South Asia, Sub-Saharan Africa

Number of Countries 144

Country(ies) Afghanistan, Algeria, Angola, Antigua and Barbuda, Argentina, Australia, Bahamas, Bahrain, Bangladesh, Barbados, Belize, Benin, Bhutan, Bolivia, Botswana, Brazil, Brunei, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Cook Islands, Costa Rica, Côte d'Ivoire, Cuba, Democratic Republic of the Congo, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Fiji, French Guiana, Gabon, Ghana, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Hong-Kong, India, Indonesia, Iran, Iraq, Israel, Jamaica, Japan, Jordan, Kenya, Kiribati, Kuwait, Lao PDR, Lebanon, Lesotho, Liberia, Libya, Madagascar, Malawi, Malaysia, Maldives, Mali, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Mongolia, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, New Zealand, Nicaragua, Niger, Nigeria, Niue, North Korea, Oman, Pakistan, Palau, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Qatar, Rwanda, Samoa, Sao Tome and Principe, Saudi Arabia, Senegal, Seychelles, Sierra Leone, Singapore, Solomon Islands, Somalia, South Africa, South Korea, South Sudan, Sri Lanka, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, Sudan, Suriname, Swaziland, Syria, Taiwan, Tanzania, Thailand, The Gambia, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Tuvalu, Uganda, United Arab Emirates, Uruguay, Vanuatu, Venezuela, Vietnam, West Bank and Gaza, Yemen, Zambia, Zimbabwe

Start Date 2012

Anticipated completion date Ongoing